Terms: = Lymphoma AND IDH1, IDP, 3417, ENSG00000138413, IDH, PICD, O75874 AND Treatment
47 results:
1. Evaluation of Immunohistochemical Expression of ALK-1 in Gliomas, WHO Grade 4 and Its Correlation with idh1-R132H Mutation Status.
Khairy RA; Momtaz EM; Abd El Aziz AM; Shibel PEE
Asian Pac J Cancer Prev; 2024 Jan; 25(1):317-323. PubMed ID: 38285799
[TBL] [Abstract] [Full Text] [Related]
2. Comparative evaluation of
Norikane T; Mitamura K; Yamamoto Y; Manabe Y; Murao M; Arai-Okuda H; Hatakeyama T; Miyake K; Nishiyama Y
J Neurooncol; 2024 Jan; 166(1):195-201. PubMed ID: 38160415
[TBL] [Abstract] [Full Text] [Related]
3. treatment regimens in patients over 64 years with acute myeloid leukaemia: a retrospective single-institution, multi-site analysis.
Sutter T; Schittenhelm M; Volken T; Lehmann T
Hematology; 2023 Dec; 28(1):2206694. PubMed ID: 38078486
[TBL] [Abstract] [Full Text] [Related]
4. Durable responses in acute lymphoblastic leukaemia with the use of FLT3 and idh inhibitors.
Madero-Marroquin R; DuVall AS; Saygin C; Wang P; Gurbuxani S; Larson RA; Stock W; Patel AA
Br J Haematol; 2024 Apr; 204(4):1238-1242. PubMed ID: 38073116
[TBL] [Abstract] [Full Text] [Related]
5. APOBEC3C is a novel target for the immune treatment of lower-grade gliomas.
Zhao S; Li Y; Xu J; Shen L
Neurol Res; 2024 Mar; 46(3):227-242. PubMed ID: 38007705
[TBL] [Abstract] [Full Text] [Related]
6.
Babakhanlou R; DiNardo C; Borthakur G
Leuk Lymphoma; 2023; 64(11):1733-1741. PubMed ID: 37462435
[TBL] [Abstract] [Full Text] [Related]
7. SOHO State of the Art Updates and Next Questions | Accelerated Phase of MPN: What It Is and What to Do About It.
Patel AA; Odenike O
Clin Lymphoma Myeloma Leuk; 2023 May; 23(5):303-309. PubMed ID: 36907766
[TBL] [Abstract] [Full Text] [Related]
8. Gene Mutations and Targeted Therapies of Myeloid Sarcoma.
Fu L; Zhang Z; Chen Z; Fu J; Hong P; Feng W
Curr Treat Options Oncol; 2023 Apr; 24(4):338-352. PubMed ID: 36877373
[TBL] [Abstract] [Full Text] [Related]
9. NCCN Guidelines® Insights: Central Nervous System Cancers, Version 2.2022.
Horbinski C; Nabors LB; Portnow J; Baehring J; Bhatia A; Bloch O; Brem S; Butowski N; Cannon DM; Chao S; Chheda MG; Fabiano AJ; Forsyth P; Gigilio P; Hattangadi-Gluth J; Holdhoff M; Junck L; Kaley T; Merrell R; Mrugala MM; Nagpal S; Nedzi LA; Nevel K; Nghiemphu PL; Parney I; Patel TR; Peters K; Puduvalli VK; Rockhill J; Rusthoven C; Shonka N; Swinnen LJ; Weiss S; Wen PY; Willmarth NE; Bergman MA; Darlow S
J Natl Compr Canc Netw; 2023 Jan; 21(1):12-20. PubMed ID: 36634606
[TBL] [Abstract] [Full Text] [Related]
10. Significance of Gene Diagnosis in Acute Myeloid Leukemia with the Emergence of New Molecular Target Drug treatment.
Yamaguchi H
J Nippon Med Sch; 2022; 89(5):470-478. PubMed ID: 36351633
[TBL] [Abstract] [Full Text] [Related]
11. Venetoclax-based salvage therapy in patients with relapsed/refractory acute myeloid leukemia previously treated with FLT3 or idh1/2 inhibitors.
Bewersdorf JP; Shallis RM; Derkach A; Goldberg AD; Stein A; Stein EM; Marcucci G; Zeidan AM; Shimony S; DeAngelo DJ; Stone RM; Aldoss I; Ball BJ; Stahl M
Leuk Lymphoma; 2023 Jan; 64(1):188-196. PubMed ID: 36287540
[TBL] [Abstract] [Full Text] [Related]
12. Current Considerations in the treatment of Grade 3 Gliomas.
Jo J; Schiff D
Curr Treat Options Oncol; 2022 Sep; 23(9):1219-1232. PubMed ID: 35913658
[TBL] [Abstract] [Full Text] [Related]
13. What to use to treat AML: the role of emerging therapies.
Thol F
Hematology Am Soc Hematol Educ Program; 2021 Dec; 2021(1):16-23. PubMed ID: 34889359
[TBL] [Abstract] [Full Text] [Related]
14. SOHO State of the Art Updates and Next Questions:Harnessing Apoptosis in AML.
Saxena K; DiNardo C; Daver N; Konopleva M
Clin Lymphoma Myeloma Leuk; 2022 Mar; 22(3):133-139. PubMed ID: 34602371
[TBL] [Abstract] [Full Text] [Related]
15. Mutant
Goldberg L; Negi V; Chung YJ; Onozawa M; Zhu YJ; Walker RL; Pierce R; Patel DP; Krausz KW; Gonzalez FJ; Goodell MA; Rodriguez BAT; Meltzer PS; Aplan PD
Cancer Res; 2021 Oct; 81(19):5033-5046. PubMed ID: 34321240
[TBL] [Abstract] [Full Text] [Related]
16. SOHO State of the Art Updates and Next Questions: idh Inhibition.
Dragani M; de Botton S
Clin Lymphoma Myeloma Leuk; 2021 Sep; 21(9):567-572. PubMed ID: 34193376
[TBL] [Abstract] [Full Text] [Related]
17. Differentiation between primary CNS lymphoma and atypical glioblastoma according to major genomic alterations using diffusion and susceptibility-weighted MR imaging.
Ozturk K; Soylu E; Cayci Z
Eur J Radiol; 2021 Aug; 141():109784. PubMed ID: 34051685
[TBL] [Abstract] [Full Text] [Related]
18. A rapid genotyping panel for detection of primary central nervous system lymphoma.
Gupta M; Burns EJ; Georgantas NZ; Thierauf J; Nayyar N; Gordon A; Jones SS; Pisapia M; Sun Y; Burns RP; Velarde J; Jordan JT; Frigault MJ; Nahed BV; Jones PS; Barker FG; Curry WT; Gupta R; Batchelor TT; Romero JM; Brastianos PK; Marble HD; Martinez-Lage M; Tateishi K; Lennerz JK; Dietrich J; Cahill DP; Carter BS; Shankar GM
Blood; 2021 Aug; 138(5):382-386. PubMed ID: 33735913
[TBL] [Abstract] [Full Text] [Related]
19. Germline ALK variations are associated with a poor prognosis in glioma and idh-wildtype glioblastoma.
Bu L; Hameed NUF; Luo C; Hong P; Zhou X; Wang S; Wu S
J Neurooncol; 2021 Mar; 152(1):27-36. PubMed ID: 33486679
[TBL] [Abstract] [Full Text] [Related]
20. Effects of azacitidine in 93 patients with
Willekens C; Rahme R; Duchmann M; Vidal V; Saada V; Broutin S; Delahousse J; Renneville A; Marceau A; Clappier E; Uzunov M; Rossignol J; Pascal L; Simon L; Micol JB; Pasquier F; Raffoux E; Preudhomme C; Quivoron C; Itzykson R; Penard-Lacronique V; Paci A; Fenaux P; Attar EC; Frattini M; Braun T; Ades L; De Botton S
Leuk Lymphoma; 2021 Feb; 62(2):438-445. PubMed ID: 33043739
[TBL] [Abstract] [Full Text] [Related]
[Next]
